- Stocks
- Pharma & Healthcare
- Sudeep Pharma
Sudeep Pharma share price
NSE: SUDEEPPHRMPharma & HealthcareDrug Manufacturers - Specialty & Generic
Sudeep Pharma at a glance
Sudeep Pharma (NSE: SUDEEPPHRM) closed at ₹984.90 on 22 Oct 2026, up 1.02% on the day. With a market capitalisation of ₹11,124 Cr, it ranks 528th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 66.2× trailing earnings, against a return on equity of 19.6% in FY26. Its 52-week range is ₹524.05 (21 Jan 2026) to ₹1,378.00 (7 Sep 2026); the last close is 28.5% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹158 Cr (+26.7% year on year) and net profit ₹41 Cr (+29.8%), on a consolidated basis. Promoters held 76.15% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹11,124 CrRank 528 on NSE
- P/E (trailing)
- 66.2×
- Price to book
- 7.57×FY26
- EPS (TTM)
- ₹16.46to Q1 FY27
- ROE
- 19.6%FY26
- ROCE
- 24.2%FY26
- Debt to equity
- 0.17FY26
- Net profit margin
- 27.1%FY26
- Book value / share
- ₹78.21FY26
- 52-week high
- ₹1,378.007 Sep 2026
- 52-week low
- ₹524.0521 Jan 2026
- RSI (14-day)
- 35.5
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +1.02% | −6.6% | −13.5% | +16.6% | — |
Sudeep Pharma quarterly results
| Quarter | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|
| Revenue | ₹116 Cr | ₹158 Cr | ₹125 Cr | ₹163 Cr | ₹172 Cr | ₹182 Cr | ₹158 Cr |
| Revenue YoY | — | — | — | — | +49.2% | +15.7% | +26.7% |
| Net profit | ₹29 Cr | ₹44 Cr | ₹31 Cr | ₹47 Cr | ₹48 Cr | ₹49 Cr | ₹41 Cr |
| Net profit YoY | — | — | — | — | +66.1% | +9.8% | +29.8% |
| Net margin | 24.8% | 28.0% | 25.0% | 28.8% | 27.7% | 26.6% | 25.6% |
| EPS | ₹2.65 | ₹4.07 | ₹2.80 | ₹4.20 | ₹4.29 | ₹4.38 | ₹3.59 |
Sudeep Pharma financials
| Item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | ₹429 Cr | ₹459 Cr | ₹502 Cr | — |
| Operating profit | ₹86 Cr | ₹175 Cr | ₹183 Cr | — |
| Net profit | ₹62 Cr | ₹133 Cr | ₹139 Cr | — |
| EPS (₹) | ₹6.00 | ₹12.00 | ₹13.00 | — |
| Cash from operations | ₹48 Cr | ₹66 Cr | ₹49 Cr | — |
| Total debt | ₹20 Cr | ₹11 Cr | ₹40 Cr | ₹34 Cr |
| Shareholders' equity | ₹223 Cr | ₹356 Cr | ₹491 Cr | ₹883 Cr |
Sudeep Pharma shareholding pattern
| Holder | 27 Nov 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|
| Promoters | 76.15% | 76.15% | 76.15% | 76.15% |
| Foreign institutions | 1.54% | 1.67% | 1.55% | 1.81% |
| Domestic institutions | 14.76% | 17.60% | 18.11% | 15.65% |
| Non-institutions | 7.54% | 4.58% | 4.18% | 6.39% |
Sudeep Pharma vs peers
The listed Pharma & Healthcare companies nearest to Sudeep Pharma by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| CORONACORONA Remedies | ₹2,024.70 | −0.26% | — | ₹12,383 Cr | 66.8 | — |
| RAINBOWRainbow Childrens Medicare | ₹1,205.70 | −0.27% | −9.4% | ₹12,245 Cr | 43.9 | — |
| SUDEEPPHRMSudeep Pharma | ₹984.90 | +1.02% | — | ₹11,124 Cr | 66.2 | — |
| METROPOLISMetropolis Healthcare | ₹532.25 | −0.03% | +9.2% | ₹11,035 Cr | 57.9 | — |
| AKUMSAkums Drugs and Pharmaceuticals | ₹690.85 | −0.17% | +50.2% | ₹10,874 Cr | 41.5 | — |
| PARKHOSPSPark Medi World | ₹220.45 | −0.74% | — | ₹9,522 Cr | 32.1 | — |
| BLUEJETBlue Jet Healthcare | ₹499.60 | +1.50% | −23.8% | ₹9,456 Cr | 35 | — |
Ask anything about Sudeep Pharma
Pivot answers on the live chart with evidence you can check, and tests strategies against SUDEEPPHRM's own history. Try: “Why has SUDEEPPHRM moved over the last three months?” · “Backtest a 50-day moving-average crossover on SUDEEPPHRM over five years” · “Compare SUDEEPPHRM with CORONA on margins and valuation”
Frequently asked questions about Sudeep Pharma
What is the share price of Sudeep Pharma today?
Sudeep Pharma (NSE: SUDEEPPHRM) last closed at ₹984.90 on 22 Oct 2026. Its 52-week high is ₹1,378.00 and its 52-week low is ₹524.05.
What is the market cap of Sudeep Pharma?
Sudeep Pharma's market capitalisation is ₹11,124 Cr (₹11,124 Cr) at the 22 Oct 2026 close, ranking 528th among the NSE companies Pivot tracks.
What is the P/E ratio of Sudeep Pharma?
Sudeep Pharma trades at a trailing P/E of 66.2. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 43.9.
What is the ROE and ROCE of Sudeep Pharma?
Return on equity was 19.6% in FY26 and return on capital employed was 24.2% in FY26 (consolidated figures).
Is Sudeep Pharma a debt-free company?
No. Sudeep Pharma's debt-to-equity ratio was 0.17 in FY26, with total debt of ₹34 Cr.
What were Sudeep Pharma's latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Sudeep Pharma reported revenue of ₹158 Cr, +26.7% year on year, and net profit of ₹41 Cr, +29.8% year on year.
What is the shareholding pattern of Sudeep Pharma?
As of 30 Jun 2026: promoters 76.15%, foreign institutions 1.81%, domestic institutions 15.65%, non-institutions 6.39%.
Who are Sudeep Pharma's competitors?
The listed Pharma & Healthcare companies closest to Sudeep Pharma by market cap are CORONA Remedies, Rainbow Childrens Medicare, Metropolis Healthcare, Akums Drugs and Pharmaceuticals, Park Medi World and Blue Jet Healthcare.
Is Sudeep Pharma a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Sudeep Pharma's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SUDEEPPHRM against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with S · all NSE stocks · this page as text